Lyndra Therapeutics president and CEO Jessica Ballinger (L) and CMO Rich Scranton

Lyn­dra’s long-act­ing risperi­done for­mu­la­tion hits PhI­II schiz­o­phre­nia tri­al end­points

Lyn­dra Ther­a­peu­tics’ schiz­o­phre­nia drug can­di­date has passed its late-stage clin­i­cal test ac­cord­ing to in­ter­im da­ta, prompt­ing an ear­ly end to the study and prepa­ra­tions for a reg­is­tra­tional safe­ty tri­al.

The Phase III STAR­LYNG-1 tri­al was de­signed to test once-week­ly LYN-005 against stan­dard of care dai­ly Risperdal in 90 peo­ple with schiz­o­phre­nia or schizoaf­fec­tive dis­or­der. LYN-005 con­tains the same ac­tive in­gre­di­ent as Risperdal — risperi­done — but was de­signed for once-week­ly dos­ing us­ing Lyn­dra’s LYNX drug de­liv­ery plat­form

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.